{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:58:38Z","timestamp":1774277918567,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Herpes zoster is an infectious disease caused by the varicella-zoster virus (VZV). In adults, the reactivation of VZV can lead to severe neuralgia and skin rashes. Although the licensed vaccines are available, their associated adverse reactions and the shortage of required adjuvants necessitate the development of novel VZV vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a novel VZV mRNA vaccine candidate (named as KH014) containing sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in an ionizable lipid nanoparticle. Its immunogenicity was evaluated in BALB\/c mice receiving single-dose, two-dose, or heterologous prime-boost regimens in comparison with the licensed adjuvanted subunit vaccine Shingrix\u00ae. Humoral responses were assessed by ELISA and microneutralization assays; cellular immunity was characterized by ELISpot, intracellular cytokine staining, and memory T-cell phenotyping via flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In mice, immunization with either a single-dose or two-dose of KH014 elicited superior VZV-specific humoral and cellular immune responses compared to the licensed vaccine Shingrix\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . Furthermore, the antigen-specific CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses elicited by a single KH014 were significantly higher and persisted for at least 10 weeks, underscoring the capacity of KH014 to induce durable protective immunity against VZV. Heterologous KH014 prime\/Shingrix\n                      <jats:sup>\u00ae<\/jats:sup>\n                      boost further enhanced cellular responses, including polyfunctional CD4\u207a and CD8\u207a T cells, and induced favorable central and effector memory T-cell profiles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The KH014 mRNA vaccine candidate induces robust and durable humoral and cellular immunity against VZV in mice, with a single dose sufficient to elicit T-cell responses superior to those of two-dose Shingrix\n                      <jats:sup>\u00ae<\/jats:sup>\n                      . These findings support further development of KH014 as a potential single-dose vaccine and inform heterologous immunization strategies to optimize protective efficacy against herpes zoster.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1771359","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:06:03Z","timestamp":1774274763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A single-dose mRNA vaccine induces potent and long-lasting humoral and cellular immunity against the varicella-zoster virus in a murine model"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenyu","family":"Cheng","sequence":"first","affiliation":[{"name":"Chengdu Kanghua Biological Products Co., Ltd.","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ren","sequence":"additional","affiliation":[{"name":"Chengdu Kanghua Biological Products Co., Ltd.","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[{"name":"Chengdu Kanghua Biological Products Co., Ltd.","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Chengdu Kanghua Biological Products Co., Ltd.","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Quan","sequence":"additional","affiliation":[{"name":"Chengdu Kanghua Biological Products Co., Ltd.","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Wei","sequence":"additional","affiliation":[{"name":"Chengdu Kanghua Biological Products Co., Ltd.","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172634","article-title":"Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity","volume":"133","author":"Laing","year":"2023","journal-title":"J Clin Invest"},{"key":"B4","first-page":"95","article-title":"Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"New Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-0127-z","article-title":"The epidemiology of herpes zoster and postherpetic neuralgia in China: Results from a cross-sectional study","volume":"8","author":"Yang","year":"2019","journal-title":"Pain Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.09.009","article-title":"Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multi-center, randomized, double-blind, placebo-controlled, phase 3 clinical trial","author":"Wang","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41541-025-01093-1","article-title":"A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses","volume":"10","author":"Munoz-Moreno","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030222","article-title":"Natural and synthetic saponins as vaccine adjuvants","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2317595","article-title":"Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients","volume":"20","author":"George","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13080882","article-title":"Decrypting the immune symphony for RNA vaccines","volume":"13","author":"Weidensee","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101111","article-title":"Structures of the varicella zoster virus glycoprotein e and epitope mapping of vaccine-elicited antibodies","volume":"12","author":"Harshbarger","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2309985","article-title":"Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques","volume":"13","author":"Huang","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41541-024-00865-5","article-title":"Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine","volume":"9","author":"Bhattacharya","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13030327","article-title":"An mRNA vaccine for herpes zoster and its efficacy evaluation in na\u00efve\/primed murine models","volume":"13","author":"Jiang","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1038\/s41467-024-53242-0","article-title":"A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128136","article-title":"Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models","volume":"72","author":"Chen","year":"2026","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101139","article-title":"Truncated VZV gE induces high-titer neutralizing antibodies in mice","volume":"12","author":"Wu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02127-19","article-title":"Persistence of varicella-zoster virus-specific plasma cells in adult human bone marrow following childhood vaccination","volume":"94","author":"Eberhardt","year":"2020","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70458","article-title":"Global disease burden of varicella-zoster virus infection: multidimensional analysis and trend projections","volume":"97","author":"Shen","year":"2025","journal-title":"J Med Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1656-7","article-title":"Immunization: vital progress, unfinished agenda","volume":"575","author":"Piot","year":"2019","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.146204","article-title":"mRNA vaccines: Emerging opportunities for herpesvirus prevention and therapeutic intervention","volume":"321","author":"Cai","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s13346-025-01961-2","article-title":"Muscle-targeting LNP vaccines enable potent immune responses against varicella zoster virus","author":"Zhang","year":"2025","journal-title":"Drug Delivery Transl Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.22.12406-12415.2004","article-title":"Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo","volume":"78","author":"Moffat","year":"2004","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2264-1","article-title":"Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design","volume":"66","author":"Chen","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of varicella-zoster virus infection","volume":"218","author":"Laing","year":"2018","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/life15040621","article-title":"Antibody titer against varicella zoster virus and recombinant varicella zoster vaccine in hemodialysis patients: What we know, what we should know","volume":"15","author":"Martino","year":"2025","journal-title":"Life (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2495607","article-title":"Varicella zoster virus mRNA vaccine candidate induced superior cellular immunity and comparable humoral and Fc-mediated immunity compared to the licensed subunit vaccine in a mouse model","volume":"21","author":"Jang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25189872","article-title":"Glycoprotein E-displaying nanoparticles induce robust neutralizing antibodies and T-cell response against varicella zoster virus","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.04.004","article-title":"T-cell immunity to human alphaherpesviruses","volume":"3","author":"Ouwendijk","year":"2013","journal-title":"Curr Opin Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_31","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab580","article-title":"Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence","volume":"225","author":"Johnson","year":"2022","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03445-13","article-title":"Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia","volume":"88","author":"Steain","year":"2014","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18609\/nai.2024.015","article-title":"Challenges and advances of the stability of mRNA delivery therapeutics","volume":"1","author":"Zhai","year":"2024","journal-title":"Nucl Acid Insights"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.10.016","article-title":"Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime\/intranasal protein boost vaccination with a combination adjuvant","volume":"32","author":"Laghlali","year":"2024","journal-title":"Mol Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.1038\/s41467-024-50087-5","article-title":"Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines","volume":"15","author":"Dong","year":"2024","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn0223","article-title":"Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice","volume":"16","author":"Cottrell","year":"2024","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S464720","article-title":"Heterologous prime-boost immunization strategies using varicella-zoster virus gE mRNA vaccine and adjuvanted protein subunit vaccine triggered superior cell immune response in middle-aged mice","volume":"19","author":"Li","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens2020364","article-title":"Animal models of varicella zoster virus infection","volume":"2","author":"Haberthur","year":"2013","journal-title":"Pathogens"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:06:10Z","timestamp":1774274770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1771359"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771359","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1771359"}}